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 Point-of-care testing (POCT) devices have received increasing attention because of their 
potential to address the urgent need for quick and accurate diagnostic tools, especially in areas of 
personal care and clinical medicine. They offer several benefits over current diagnostic systems, 
including rapid diagnostic results in comparison to microbial cultures, simple interpretation of results, 
portability, and requiring no specialised laboratory equipment or technical training to operate. These 
are essential for diagnosing critical illnesses, such as sepsis, in areas of poor healthcare infrastructure. 
Sepsis, an innate physiological response to infection, is a growing problem worldwide with high 
associated costs and mortality rates, and affects a wide range of patients including neonates, infants, 
the elderly, and immunocompromised individuals. 
 A literature review of the biomarkers of sepsis and the currently available diagnostic systems 
indicates the need for a biosensor capable of meeting the requirements of designing POCT systems 
and achieving detection of low concentrations of biomarkers. To meet these demands, two significant 
contributions to developing POCT platforms have been achieved and described in this thesis, 
including: 1) development of a colorimetric, magnetically separable biosensor that can be easily 
fabricated and demonstrates an easily identifiable colour response upon analyte detection, as well as 
the ability to capture and detection target biomarkers at low concentrations from complex solutions; 
and 2) tuning of the biosensor’s colorimetric response to achieve low detection limits, as well as 
demonstration of the versatility of the biosensor for sensing different target analytes. The developed 
biosensor in this work combines colour responsive polydiacetylenes and superparamagnetic iron 
oxide for the first time to achieve a biosensor capable of meeting these demands. The sensors exhibit 
identifiable colour responses to biomolecule detection, capture of a target analyte from complex 
solutions, sensing of different target analytes, a lower detection limit of 0.01 mg/mL, and rapid 
separation from solution with a common magnet. This work has been a significant demonstration of 
the capabilities of this biosensor as a new platform for POCT systems to diagnosis sepsis, and 




I would like to acknowledge my supervisor Frank Gu and the members of the Frank Gu Research 
Group for their ongoing support throughout this project, especially Mohit Verma and Tim Leshuk for 




I dedicate this thesis to my family, especially my mom, for their extraordinary love and sacrifice to 
support my continuing education. 
 
 vi 
Table of Contents 




Table of Contents .................................................................................................................................. vi 
List of Figures ..................................................................................................................................... viii 
List of Tables ......................................................................................................................................... ix 
1.0 Introduction ...................................................................................................................................... 1 
1.1 Point-of-care testing ..................................................................................................................... 1 
1.2 Sepsis ............................................................................................................................................ 1 
2.0 Literature Review ............................................................................................................................. 3 
2.1 Biomarkers of sepsis..................................................................................................................... 3 
2.2 Biomarkers for bacterial causes of sepsis ..................................................................................... 4 
2.2.1 C-reactive protein .................................................................................................................. 4 
2.2.2 Procalcitonin .......................................................................................................................... 5 
2.2.3 Serum amyloid A ................................................................................................................... 6 
2.3 Biomarkers for fungal causes of sepsis ........................................................................................ 6 
2.4 Biomarkers for viral causes of sepsis ........................................................................................... 7 
2.5 Other biomarkers requiring further research ................................................................................ 8 
2.6 Currently available assays ............................................................................................................ 9 
2.6.1 Assays for C-reactive protein ................................................................................................ 9 
2.6.2 Assays for procalcitonin and serum amyloid A ................................................................... 10 
2.6.3 Assays for mannan and anti-mannan ................................................................................... 12 
2.6.4 Assays for interferon-γ-inducible protein 10 ....................................................................... 12 
2.7 Commentary on sepsis biomarker research ................................................................................ 13 
2.8 Five year outlook ........................................................................................................................ 14 
3.0 Research objectives ........................................................................................................................ 16 
3.1 Sensor development for biomolecule detection objectives ........................................................ 16 
3.2 Sensor tuning objectives ............................................................................................................. 17 




4.1 Introduction ................................................................................................................................ 19 
4.2 Experimental Methods ................................................................................................................ 20 
4.2.1 Synthesis of hydrophobic superparamagnetic iron oxide nanoparticles .............................. 20 
4.2.2 Amphiphilic modification of diacetylene monomer ............................................................ 21 
4.2.3 Fabrication of Lys-PCDA/SPION core-shell particle ......................................................... 21 
4.2.4 Detection of anti-bovine serum albumin antibodies ............................................................ 21 
4.3 Results and Discussion ............................................................................................................... 22 
4.3.1 Characterisation of Lys-PCDA/SPION-based biosensors ................................................... 22 
4.3.2 Colorimetric performance of Lys-PCDA/SPION sensors ................................................... 23 
4.4 Conclusions ................................................................................................................................ 26 
5.0 Optimisation of polydiacetylene-coated superparamagnetic iron oxide for colorimetric detection 
and capture of biomarkers .................................................................................................................... 27 
5.1 Introduction ................................................................................................................................ 27 
5.2 Experimental Methods ................................................................................................................ 27 
5.2.1 Materials .............................................................................................................................. 27 
5.2.2 Synthesis .............................................................................................................................. 28 
5.2.3 Biosensor fabrication ........................................................................................................... 28 
5.2.4 Antibody assay .................................................................................................................... 28 
5.2.5 Characterisation ................................................................................................................... 28 
5.3 Results and discussion ................................................................................................................ 29 
5.3.1 Optimisation of polydiacetylene amount used in sensor fabrication ................................... 29 
5.3.2 Optimisation of colorimetric biomolecule detection ........................................................... 32 
5.4 Conclusions ................................................................................................................................ 37 
6.0 Conclusions and Recommendations ............................................................................................... 38 
6.1 Concluding Summary ................................................................................................................. 38 
6.2 Recommendations for Future Work ........................................................................................... 39 






List of Figures 
Figure 1. A possible strategy for diagnosing the type of infectious cause of sepsis ...................... 14 
Figure 2. Schematic representation of colorimetric, magnetically separable functionalised Lys-
PCDA/SPION particles, describing the capturing and sensing of a target biomolecule from a 
complex solution ................................................................................................................................. 20 
Figure 3. Demonstration of the colorimetric and magnetic properties of Lys-PCDA/SPIONs ... 23 
Figure 4. Biosensor performance of BSA-functionalised Lys-PCDA/SPIONs ............................. 25 
Figure 5. Characterisation of Lys-PCDA/SPION sensors .............................................................. 31 
Figure 6. Photographs of Lys-PCDA/SPION sensors of varying PDA wt% ................................. 32 
Figure 7. Absorption spectra of Lys-PCDA/SPION sensors of varying PDA wt%, normalised to 
650 nm ................................................................................................................................................. 33 
Figure 8. Absorption spectra of Lys-PCDA/SPION sensors of 80-95 wt% PDA, normalised to 
650 nm, in increasing horse IgG concentrations .............................................................................. 34 
Figure 9. Absorption spectra of Lys-PCDA/SPION sensors of 60-75 wt% PDA, normalised to 
650 nm, in increasing horse IgG concentrations .............................................................................. 35 
Figure 10. Colorimetric response of 85, 90 and 95 wt% PDA compositions of Lys-PCDA/SPION 




List of Tables 
Table 1. Summarising the components of diagnostic accuracy of a biomarker. ............................ 3 
Table 2. Reported diagnostic accuracy values of C-reactive protein, procalcitonin, serum 
amyloid A, mannan, anti-mannan, and interferon-γ-inducible protein 10. .................................... 8 
Table 3. Available assays measuring CRP. ...................................................................................... 10 
Table 4. Available assays measuring procalcitonin. ........................................................................ 11 
Table 5. Available assays measuring serum amyloid A. ................................................................. 12 
 1 
1.0 Introduction 
1.1 Point-of-care testing 
 The past decade in diagnostics has seen an increasing demand for point-of-care testing 
(POCT) devices to address the urgent need for quick and accurate diagnostic tools, especially in areas 
of personal care and clinical medicine. Existing rapid and/or automated diagnostic systems used in the 
clinical setting are based on molecular sensing-techniques, such as such as enzyme-linked 
immunosorbent assay, polymerase chain reaction, and fluorescence in situ hybridisation. The 
molecules targeted are termed biomarkers, which are best described as “a characteristic that is 
objectively measured and evaluated as an indicator of normal biologic processes [or] pathogenic 
processes”.1 These biomarker-based diagnostic systems typically operate by monitoring abnormal 
changes in specific biomarker concentrations found in bodily fluids, which are indicative of a disease 
state. 
 Similar to existing rapid molecular-based diagnostic systems, point-of-care testing devices 
are biomarker-based systems designed to produce quick diagnostic results, ideally within several 
minutes to under an hour. In addition, POCT devices offer several advantages over existing rapid 
diagnostic systems, including: requiring no expertise or specialised training to operate; providing 
easily interpretable diagnostic results; being extremely portable and self-contained; and requiring no 
complex or technique-dependent manipulations of the samples.2-4 These features become inherently 
useful in rural and low income communities and other areas of poor healthcare infrastructure, where 
specialised laboratory equipment and highly trained technicians are commonly not available. POCT 
systems have the potential to perform similarly to lab diagnostic techniques and have been previously 
demonstrated to this effect in the clinical field, such as the early diagnosis of HIV patients when 
compared to a flow cytometry technique in the laboratory setting.5 Ideal POCT devices should also be 
relatively simple to manufacture if their target usage is in rural and low income communities. 
Consequently, the practicality of such devices extends beyond medicine to other applications ranging 
from food safety to hazardous material detection. 
1.2 Sepsis 
 In clinical medicine, point-of-care testing devices are critically needed for diagnosing 
diseases with rapidly-developed adverse effects. One such disease is sepsis, which is a growing 
worldwide problem worldwide and associated with a mortality rate as high as 60%.6, 7 Although 
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sepsis is not a true disease but rather an innate physiological response by the immune system to 
infection,8 it is estimated that severe sepsis affects over 750,000 people in the United States alone 
each year, resulting in an annual cost of almost $17 billion,9 underscoring the costly consequences of 
sepsis. It is a highly detrimental problem for those with weakened immune systems, including 
infants,10-14 the elderly and immunocompromised and critically ill patients.15 Sepsis remains a 
common and similarly expensive problem in developing nations, where sepsis is known to affect up 
to every 30 of 1000 live births.16, 17 
 Most studies define sepsis as a systemic inflammatory response to bacterial, fungal, or viral 
infections.8, 18 In the clinical setting, several other physiological symptoms must be presented to 
diagnose sepsis, which often delays the diagnosis of sepsis.19-21 As a result, the common treatment for 
patients suspected of sepsis is the administration of broad spectrum antimicrobials.22, 23 The gold 
standard of diagnosing sepsis has traditionally been the use of microbial cultures to identify the 
source of illness.6, 17 However, the major limitation of using cultures is the length of time required to 
develop cultures to identifiable quantities. Cultures are also reported to be insensitive under several 
conditions, 24-28 including slow growing and non-cultivatable microorganisms and microorganisms 
present at very low concentrations. In light of these limitations and the widespread problem of sepsis 
in developing nations, POCT devices are ideal systems for the diagnosis of sepsis. 
 This thesis describes the work done in the development of a colorimetric, magnetically 
separable sensor for future applications in point-of-care testing systems, specifically for the diagnosis 
of sepsis. Before describing the project design and its objectives, a comprehensive literature review of 
the most commonly studied sepsis biomarkers that are directly quantifiable from human serum is 
presented, since POCT devices operate with minimal sample manipulation. An overview of 
commercially available diagnostic systems used for sepsis biomarkers is also provided to identify the 




2.0 Literature Review 
 The following literature review has been published in Expert Review of Molecular 
Diagnostics, June 2011, volume 11, issue 5, pages 487-96, authored by Terence Chan and Frank Gu, 
adapted with permission of Expert Reviews Ltd. 
2.1 Biomarkers of sepsis 
 To be considered clinically relevant, a biomarker must have high diagnostic accuracy (DA):29 
it must have high sensitivity, specificity, positive predictive value (PPV), and negative predictive 
value (NPV) (Table 1). Many biomarker also calculate the likelihood ratio (LR) to determine if test 
results are truly indicative of disease or due to random chance. Indicators such as the positive and 
negative likelihood ratios, which are calculated based on sensitivity and specificity, are also useful for 
assessing the strength of a diagnostic test. It is commonly graphed for multiple cutoff values as a 
receiver operating characteristic curve. The area under the curve (AUC) value is used to determine 
the best diagnostically relevant cutoff value (CV). At a CV where the AUC is equal to 1, an ideal 
biomarker would possess 100% sensitivity, specificity, PPV, and NPV. 
 Since sepsis can be caused by bacterial, fungal, and viral infections, the biomarkers reviewed 
are categorised based on their most common diagnostic usage. 
Table 1. Summarising the components of diagnostic accuracy of a biomarker. 
Diagnostic measure Definition 100% indicates 
Sensitivity 
True Positives
True Positives + False Negatives  




True Negatives + False Positives  
All detected healthy samples are truly 
healthy 
Positive predictive value 
True Positives
True Positives + False Positives  
Only truly diseased samples are 
detected as diseased 
Negative predictive value 
True Negatives
True Negatives + False Negatives  
Only truly healthy samples are 
detected as being healthy 
Positive likelihood ratio 
Sensitivity
1 – Specificity  
Ratio specifies that a positive test 
outcome is more likely to indicate a 
diseased state. 
Negative likelihood ration 
1 – Sensitivity
Specificity   
Ratio specifies that a negative test 




2.2 Biomarkers for bacterial causes of sepsis 
2.2.1 C-reactive protein 
 C-reactive protein (CRP) is a general acute-phase reactant protein that rises in concentration 
up to 1000-fold in the blood in response to inflammation and infection.1, 20, 23, 29-34 Sensitivity values 
have been reported from 30-97.2%, specificity of 75-100%, PPV of 31-100%, and NPV of 81-97% 
(Table 2).11, 23, 30, 32, 35-39 The large disparity in diagnostic accuracy values is mainly due to the wide 
range of cutoff values used in different studies, ranging from 0.2-110 mg/L. The rapid improvement 
of assays used in studies to detect CRP has also dramatically affected the determined CVs. A 2003 
study on neonates reported a CV of 40 mg/L when using the NycoCard CRP test,39 whereas a 2010 
study on neonates using the automated immunoassay IMx system reported CVs of 0.2-0.6 mg/L.38  
 The variation in results can also be caused by the use of different assays. Each assay has a 
unique functional detection limit. Among the 15 different studies reviewed that measured CRP and 
mentioned the equipment used, 10 different assay systems from various manufacturers were used. 
The variation in equipment also reflects the various different study designs between studies. While 
some studies focus on neonates,11, 19, 30, 35, 37, 39-41 others focus on children,31, 35-37, 39, 42, 43 adults,31, 32, 41, 
44-48 and the elderly.25, 31, 38, 41 Serum CRP levels also vary with age in healthy individuals.41 The 
authors of the study suggested that a CV of 10 mg/L be used for elderly patients over 65, while a CV 
of 5 mg/L should be used for adults and infants between 3-7 days old. CRP levels are also naturally 
higher in older children compared to younger children.42 
 Studies have shown CRP to be highly sensitive 11, 25, 37, 39, 44 or highly specific 30, 35 for 
infection. However, it is unclear if CRP can be used to distinguish Gram positive from Gram negative 
bacterial infections.44 CRP is also studied as a diagnostic marker for other illnesses.23, 38, 47, 49, 50 A 
recent study on community-acquired pneumonia (CAP) showed CRP as a prognostic marker in 
determining the severity of CAP and the need for hospitalisation when using a CV of 110 mg/L.38 
CRP is also reported to distinguish bacterial from fungal infections, where levels above 100 mg/L are 
indicative of bacterial infection and elevated levels below 100 mg/L are indicative of fungal 
infection.25, 45 Several studies have examined the diagnostic relevancy of CRP in viral infections,47, 51, 




 Procalcitonin (PCT), a precursor to the hormone calcitonin, is another candidate biomarker 
for bacterial infection. It is reported to be present at very low concentrations of 0.033 ng/mL in the 
serum of healthy individuals,21 and is known to increase by up to 1000-fold under inflammatory 
conditions.21, 53-55 It is reported to rise within 2-4 hours of infection and peak at 6-8 hours.10, 19, 54 
Persistent elevated levels are indicative of the continual presence of infection or sepsis.21 The rapid 
upregulation and sustainment of PCT levels in the serum during infection makes it an ideal 
biomarker. It is also a stable molecule, an important biomarker quality, remaining stable during blood 
preparation methods and freezing procedures and after long-term storage.37, 56, 57 
 PCT has been shown to have high diagnostic accuracy, reporting sensitivity values of 74.8-
100%, specificity values of 70-100%, PPV of 55-100%, and NPV of 56.3-100% (Table 2).10, 15, 25, 32, 36, 
37, 39, 53 Similar to the studies on CRP, the variation in diagnostic accuracy values can also be 
explained by variations in cutoff values, equipment used, and study designs. Although many studies 
have used a cutoff value of 0.5 ng/mL, a range of CVs have been reported (Table 2). A 2001 study on 
critically ill children with sepsis reported a CV of 8.05 ng/mL, using an immunoluminometric assay 
available at the time.39 In comparison, a 2009 study on critically ill children with sepsis determined a 
CV of 0.28 ng/mL, using the newer immunoluminometric LIAISON BRAHMS PCT assay.35 
 As a biomarker for bacterial infection, most studies find PCT to be a useful and accurate 
biomarker 19, 21, 58-61 and more useful than other common inflammatory markers.25, 32, 36, 39, 42, 53, 62 
Several studies have reported significantly elevated levels of PCT in patients with sepsis compared to 
those without sepsis.15, 21, 23, 25, 26, 31, 46, 53, 54, 63 Studies have also reported PCT being used as a 
prognostic marker, indicating that levels of PCT are a good indicator of response to treatment,54, 62, 64, 
65 severity of sepsis,25, 54 and mortality from sepsis.31, 54, 66 Similar to the case of CRP, it is unclear if 
PCT can be used to distinguish between Gram positive and Gram negative bacterial infections,21, 32, 62 
which are treated with different strategies.  
 PCT has also been used to distinguish fungal and viral infections from bacterial infections. 
During viral infections, PCT levels are reported to remain at low levels, often at concentrations found 
in healthy individuals.21, 54, 64 A study on 122 children with viral infection reported that the maximum 
PCT level observed was 0.7 ng/mL.67 PCT can also be used to differentiate bacterial from viral 
meningitis.54, 61 In comparison, fungal infections tend to cause mild elevations in PCT concentration 
compared to levels seen in bacterial infections.21, 25, 45, 53, 54, 62 Studies on invasive aspergillosis and 
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invasive candidasis have reported significantly higher levels of PCT in patients with bacterial sepsis 
than those with fungal infection.25, 45 PCT also shows potential as a diagnostic marker for pneumonia, 
abdominal infections, urinary tract infections, lower respiratory tract infections, and myocardial 
infarction.49, 54, 56, 59, 64, 65, 68 It has also been demonstrated as a biomarker to guide antibiotic therapy in 
patients with CAP.29, 55, 62, 65, 69, 70 
2.2.3 Serum amyloid A 
 Serum amyloid A (SAA) is an apolipoprotein reported to have potential for diagnosing 
sepsis.10, 30 SAA is expressed up to 1000 times higher in 8-24 hours of sepsis.10, 71 Compared to CRP 
levels, SAA levels are reported to rise faster and higher after the onset of sepsis and remain at higher 
relative elevations.30 Similar to PCT and CRP, studies using SAA have reported various diagnostic 
accuracy values and cutoff values (Table 2), likely a result of the different assays used, as well as the 
development of assays with lower detection limits. Serum SAA levels of <15 mg/L for the elderly 
over 65 and <10 mg/L for adults and newborns aged 3-7 days are indicative of healthy states.23 
 Although SAA is mainly studied as a biomarker for bacterial infection, a recent study on 
patients with viral infections reported elevated SAA levels above the healthy cutoff of 10 mg/L 
among the infected patients.47 However, SAA may not be clinically useful because it was too 
sensitive, as it was reported in the same study to increase during minor viral infections and in patients 
not presenting symptoms. 
2.3 Biomarkers for fungal causes of sepsis 
 Mannan and anti-mannan antibodies (M+AM) are used exclusively to diagnose invasive 
fungal infections, due to the presence of mannan in the cell walls of the invasive fungal organisms.28 
M+AM levels are elevated in blood during invasive fungal infections,45 such as candidiasis and 
aspergillosis, making them potentially useful biomarkers for diagnosing fungal causes of sepsis. 
Reported diagnostic accuracy values and cutoff values for M+AM vary between studies, and are 
either measured as separate biomarkers 45, 72 or in combination 72, 73 (Table 2). It has been reported that 
combining mannan and anti-mannan tests provides the best diagnostic accuracy values.72 Similar to 
the biomarkers used for bacterial infections, DA value variations are likely due to the different assays 
and study methodologies. Assays with lower detection limits are also required, as all three studies 
reviewed reported cutoff values lower than the manufacturer’s suggested diagnostic CVs. 
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 The main disadvantage of using M+AM tests alone is the high rate of false-positives and 
false-negatives that mannan assays produce,28 requiring that these tests be used in conjunction with 
other diagnostic tests. β-D-glucan (BDG) tests have been used in combination with M+AM tests since 
BDG tests are highly sensitive and specific for invasive mycosis, and not species specific.28, 73 Using 
M+AM as biomarkers also requires frequent serial measurements, as mannan is cleared relatively 
quickly from the blood.28, 74 
2.4 Biomarkers for viral causes of sepsis 
 Interferon-γ-inducible protein 10 (IP-10), a proinflammatory chemokine, is a promising a 
biomarker for diagnosing viral infections due to its role in the host response to viral infections.75 A 
recent study on bacterial infections in very low birth weight infants concluded that IP-10 could be a 
good diagnostic marker during initial measurements, reporting significant elevated IP-10 levels in 
infected patients at both initial and 24 hour measurements, with no overlap of ranges. IP-10 levels 
may also correlate with the severity of infection.75 
 Differences in diagnostic accuracy values and cutoff values exist between IP-10 studies 52, 75, 
76 (Table 2), a result of the complex nature of viral infections. The large variety of viral illnesses 
means studies must focus on a specific virus infection, requiring very specific study populations and 
assays. However, current studies report IP-10 to be a potentially useful biomarker.52, 75, 76 It is known 
from previous studies that IP-10 is released in response to viruses such as rhinovirus, RSV, hepatitis 
B and C viruses, and H5N1 influenza.76, 77 In addition, IP-10 in the serum has been shown as a 




Table 2. Reported diagnostic accuracy values of C-reactive protein, procalcitonin, serum 
amyloid A, mannan, anti-mannan, and interferon-γ-inducible protein 10. 
Biomarker Cutoff Value 
Diagnostic Accuracy Values (%) 
Studies 
Sensitivity Specificity PPV NPV 
CRP 1.56-110 mg/L 30-97.2 75-100 31-100 81-97 
11, 23, 30, 32, 35-
39 
PCT 0.3-8.05 ng/mL 74.8-100 70-100 55-100 56.3-100 
10, 15, 25, 32, 36, 
37, 39, 53 
SAA 8-68 mg/L 76.4-98.4 92.3-100 85-100 58-99 10, 30, 39 









67-93 59.4-89 77** 97** 52, 75, 76 
Note: AM – anti-mannan; AU  – arbitrary units; CRP – C-reactive protein; IP-10 – interferon-γ-inducible 
protein 10; M – mannan; NPV – negative predictive value; NS – not stated; PCT – procalcitonin; PPV – 
positive predictive value; SAA – serum amyloid A; * – cutoff value for AM; ** – reported only by one study. 
2.5 Other biomarkers requiring further research 
 Interleukin 10 (IL-10) is a potentially useful biomarker of sepsis. IL-10 is reported to be a 
promising diagnostic marker of both early- and late-onset sepsis among neonates, where a cutoff 
value of >17.3 pg/mL resulted in respective diagnostic accuracy values of 92%, 84%, 80%, and 
89%.20 A study on very low birth weight infants found IL-10 to be one of only three markers with 
diagnostically relevant sensitivity and specificity values (≥80%) when using a CV of 7.6 pg/mL for 
late-onset sepsis.75 In general, circulating cytokines, such as interleukins, have a short half-life, which 
can result in false negatives, ultimately limiting their diagnostic accuracy.19, 30 
 A potentially useful biomarker specific to bacterial infections is lipopolysaccharide binding 
protein (LBP). Serum LBP levels are known to increase during bacterial and fungal infections, but not 
viral infections.79 A study on critically ill neonates and children with sepsis reported LBP to be a 
better biomarker for sepsis than PCT, CRP, and soluble CD14.79 Soluble triggering receptor 
expressed on myeloid cells-1 (sTREM-1) is another potential biomarker, as it is not upregulated 
during non-infectious inflammatory diseases,65 a property not found in other biomarkers like PCT. A 
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recent study reported significantly elevated plasma sTREM-1 levels in sepsis patients compared to 
SIRS patients and found it to be a diagnostically accurate biomarker.46 
 Toll-like receptor 2 (TLR-2) and neutrophil CD64 receptor (nCD64) are two potentially 
useful biomarkers only present on cell surfaces. During infection, both experience upregulated 
expression on the surface of monocytes 47 and neutrophils,35, 80 respectively. A recent study found 
significantly elevated TLR-2 expression during viral and bacterial infections.47 The study used 
patients with influenza A and B, RSV, mumps, varicella-zoster virus, and cytomegalovirus, indicating 
TLR-2 could be a potential biomarker of viral infections. nCD64 has been widely used as a sensitive 
biomarker of bacterial infection in settings that allow for laboratory testing.81 nCD64 expression is 
not affected by underlying or inflammatory diseases and is not differentially expressed between 
systemic and local bacterial infections.80 Although different studies have used differing units to 
calculate the CVs, the DA values reported for nCD64 are generally diagnostically relevant. For 
example, reported sensitivity values range from 71-97%, 71-100% for specificity, 53-100% for PPV, 
and 75.9-98% for NPV.15, 20, 35, 80, 82, 83 
2.6 Currently available assays 
2.6.1 Assays for C-reactive protein 
 Various assays have been designed for measuring CRP, briefly summarised in Table 3.
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Sample used Study used 
IMx system Abbott Laboratories 0.05 mg/La Serum 40 
BN II analyzer Dade Behring 5 mg/L Serum 10 
BN ProSpec analyzer Dade Behring 0.16 mg/L Serum 23, 41 
CRPLX Tina-quant kit Roche-Hitachi 0.4 mg/L Serum 30, 38, 43, 66 
Advia 1650 analyzer 
Bayer HealthCare 
Diagnostics 
N/A Serum 48 





3 mg/L Serum 35 




7 mg/L Plasma 42 
QuickRead CRP Orion Diagnostica 8 mg/L 
20 μl of whole 
blood 
11 
NycoCard CRP Axis-Shield PoC AS 8 mg/L 
5 μl of whole 
blood 
11, 36, 37 
Note: ‡ - if functional sensitivity values were not made available, the reported lower detection limits are listed, 
which may be lower than the functional sensitivity values; a – stated in [90]; b – stated on manufacturer’s 
website; N/A – not available. 
 QuickRead CRP, an immunoturbidometric assay, and NycoCard CRP, a chromatographic 
immunometric assay, are especially interesting for diagnostics purposes because of the fast run times. 
A recent study compared the two CRP assay kits on neonates with sepsis.11 Using a CV of 10 mg/L 
for both kits, the QuickRead CRP kit produced diagnostic accuracy values of 97.2% sensitivity, 
80.6% specificity, 83.3% PPV, and 96.7% NPV, while the NycoCard CRP kit produced DA values of 
94.4%, 83.3%, 85%, and 93.8% respectively, demonstrating that both kits showed similar 
performance and provided diagnostically relevant results. 
2.6.2 Assays for procalcitonin and serum amyloid A 
 Many assays have been developed to measure PCT, mainly manufactured by BRAHMS. 
They are briefly summarised in Table 4.  
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BRAHMS 0.5 ng/mL 2.75 hours 
20 μl of 
serum 
10, 15, 21, 31, 
37, 39, 45, 46, 
64  





DiaSorin 0.1 ng/mL 40 minutes Serum 25, 35, 84 
Kryptor – TRACE assay BRAHMS 0.06 ng/mL 
50 minutes, 19-
45 minutes** 
Serum 56, 64, 66, 84 
PCT kit – ELISA USCNLIFE 7.8 pg/mL 4.5-5 hoursa 






bioMérieux 0.09 ng/mL 20 minutes Serum 






BRAHMS 0.5 ng/mL 20-45 minutes 
200 μl of 
serum or 
plasma 
32, 36, 42, 57, 
59, 84 
Note: * – revised version; ** – subsequent serial measurements; ‡ if functional sensitivity values were not made 
available, the reported lower detection limits are listed, which may be lower than the functional sensitivity 
values; a – stated on manufacturer’s website. 
 PCT assay developments have notably improved the functional detection limits and the run 
times, such as the recently developed Kryptor and VIDAS assays. A recent study reported that the 
Kryptor and VIDAS systems could be interchangeably used in the clinical setting when using the 
same cutoff values.56 Of interesting note is the semi-quantitative PCT-Q kit, made commercially 
available by BRAHMS as a point-of-care testing (POCT) kit. Results are indicated by one of four 
different shades of a red coloured band, each of which corresponds to a different range of PCT 
levels.42, 57 The ranges indicate the possibility and severity of sepsis. Although the kit is designed to 
require no specialised training to operate and interpret results, the semi-quantitative nature means that 
test results are subject to the operating technician’s interpretation.57 User difficulties in interpreting 
results have been reported, and its results only showed moderate agreement compared to the Kryptor 
assay when used in the clinical setting.57 
 Similar to PCT and CRP, multiple assays exist to measure SAA (Table 5). 
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Sample used Study used 
BN II analyzer Dade Behring 68 mg/L Serum 10, 39 
BN ProSpec analyzer Dade Behring 0.758 mg/L Serum 23, 48 
IMx system Abbott Laboratories 0.02 mg/La Serum 40 
SAA ELISA kit BioSource International 1.9 mg/L Serum 47 
LZ TEST “Eiken” 
SAA kit 
Eiken Chemical Co. Ltd 0 mg/L 3 μl of serum 30 
N Latex SAA kit 
Siemens Healthcare 
Diagnostics 
0.75 mg/Lb Serum 43 
Note: ‡ if functional sensitivity values were not made available, the reported lower detection limits are listed, 
which may be lower than the functional sensitivity values; a – stated in 85; b – stated in manufacturer’s brochure. 
 It is interesting to note that the LZ TEST “Eiken” SAA Kit has been cited as a fully 
automated rapid kit requiring no specialised equipment, with a detection range of 0-386 μg/mL.30 
2.6.3 Assays for mannan and anti-mannan 
 Assays measuring mannan and anti-mannan concentrations are predominantly made by Bio-
Rad Laboratories. These quick tests already exist because cultures for fungal infections are often 
insensitive and time intensive.73 These include: the Platelia Candida-specific antigen and antibody 
ELISA kit, with manufacturer suggested cutoff values of 0.5 ng/mL for mannan and 10 AU/mL for 
anti-mannan;73 and the Platelia Aspergillus-specific antigen immunoassay, with a manufacturer 
suggested CV of 1.5 ng/mL for mannan.45 There also appears to be an updated version of the assay kit 
for the Candida species, with manufacturer suggested CVs of 0.25 ng/mL for mannan and 5 AU/mL 
for anti-mannan.72 Enzyme immunoassays with greater sensitivities have also been developed.74 
2.6.4 Assays for interferon-γ-inducible protein 10 
 No quick diagnostic assay for IP-10 are available yet. The assays used in studies utilise 
different measurement methods, including: a cytometric bead array kit (BD Biosciences Pharmingen) 
with a lower limit of 2.8 pg/mL, able produce results in 4 hours using 50 μl of plasma;75 a 
commercially available sandwich ELISA kit (R&D Systems) with a lower limit of 1.67 pg/mL, able 




2.7 Commentary on sepsis biomarker research 
 The main challenge facing future biomarker research, and in reviewing biomarker studies, is 
the lack of standard operating protocols for each specific biomarker. There is high variability in study 
designs, including small sample sizes,25, 32, 35-39, 42-46, 48, 63, 76 heterogeneous population types,31, 32, 35, 46 
population type specificity,25, 36, 38, 45, 46, 63 and high variation in assay equipment. Several studies also 
suffer from poor presentation and/or application of statistical analysis of data,10, 25, 31, 32, 35-37, 39, 40, 42-45, 
48, 53, 63 which may lead to improper interpretation of results by the readers. Many studies are single-
centre studies involving small sample sizes, which may result in incorrect representation of the 
general population, but this restriction is a result of the high costs of running studies in the clinical 
setting and incorporating multiple centres. However, other issues pertaining to study design requires 
the establishment of standardisation among biomarker research studies.21, 58, 62 Efforts have already 
been made to establish reporting and analysis standards, such as STARD 86, 87 and GRADE 88, 89 
respectively, and the research community should endeavour to adopt these standards on a global scale 
for all future studies. 
 Although CRP and PCT are both commonly studied biomarkers for sepsis and infection, 
some studies suggest neither can be used in singular capacities. CRP shows a 12-24 hour delay in 
elevated levels to infection,20, 58 so it may not be a sensitive marker during initial measurement.75 
Serum PCT levels can naturally rise 3-24 hours after exercise.58 In newborn infants, PCT also 
naturally increases to 2-3 ng/mL at 24 hours after birth, returning to normal levels at 48-72 hours after 
birth.54 A few non-infectious diseases and conditions can also cause abnormally elevated levels of 
CRP 10, 19, 41, 80 or PCT.21, 30, 58 In addition, some studies report CRP 30, 32, 35, 39, 42, 46, 75, 83 and PCT 15, 20, 
27, 31, 35 to be less diagnostically relevant than other potential biomarkers of sepsis. The current 
research suggests that a singular “ideal” biomarker of perfect diagnostic relevance and accuracy does 
not yet exist.19 However, the many studies reporting the usefulness of CRP, PCT, and other molecules 
as biomarkers of sepsis cannot be ignored. To overcome this issue, multiple biomarkers must be used 
in combination to provide definitive diagnostic test results. 
 A possible strategy is described in Figure 1. Many of the studies reviewed have also 
demonstrated the use and/or need of measuring multiple markers in combination,10, 21, 31, 35, 40, 45, 53, 64, 65, 
72, 73 generally reporting improved DA values. POCT kit developers are also calling for the 
development of multiplex assays for various diseases,2-4, 90 emphasising the need and benefits of 
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relevancies are standardisation in study methodology and use of assays with better detection limits. 
Assays capable of lower functional detection limits should be readily available for these purposes as 
several are already in development, while new technologies will allow improvements to existing ones. 
The ongoing development of POCT kits for other diseases may also be beneficial for sepsis 
biomarker research. Designs from these kits can be applied towards developing a sepsis diagnostic kit 
that may ultimately provide greater accuracy and faster results over current assays. The 
standardisation of study methodology is a complicated task and may not occur within the next five 
years. Researchers should seize the opportunity at current annual conferences on sepsis and 
biomarker research to achieve some consensus on methodology standards.  
 In parallel, general consensus in the scientific community regarding the diagnostic 
relevancies of the current sepsis biomarkers needs to be established within the next few years. 
Consequently, the direction of research will need to evolve from single-centre to multi-centre studies 
to reduce the limitation of generalisation of small data sets. Sepsis often presents alongside other 
conditions. Due to this complexity, a single “golden” biomarker may not exist, thus research should 
shift more focus on assessing the combined diagnostic capabilities of multiple biomarkers.  
 Complementary research paths also exist and should be explored. Firstly, as sepsis results 
from systemic infection, the most diagnostically relevant sepsis biomarkers should be studied for their 
potential towards early diagnosis of general infections. Results from these studies can be applied to 
the development of POCT kits designed to monitor sudden homeostatic imbalances, indicating the 
body is diseased before symptoms are presented. Secondly, some research should be devoted to 
designing and testing a rigorous, multiplex POCT kit for sepsis within the next five years, which 
would be beneficial for both method standardisation in future research and clinical usage in rural and 




3.0 Research objectives 
 This thesis focuses on the development of a colorimetric, magnetically separable sensor for 
the capture and detection of biomarkers, based on a surface-functionalised core-shell particle design. 
Delivering a colorimetric response to biomolecule detection was desired in order to produce an easily 
identifiable sensing signal that could be observed without specialised laboratory equipment. To 
accomplish this objective, a sensing system capable of amplifying the detection of small protein 
concentrations was required. Magnetic separability was also desired because it would offer two main 
benefits. First, it would allow the design of a solution-based sensor, advantageous over solid-state 
systems because of the increased probability of interactions between sensor and analyte, as well as 
allowing biomolecule-based analytes to preserve their native form and function.91 Second, magnetic 
separability would achieve simple, rapid separation of captured targets from complex solutions, 
thereby allowing the sensor to be used with non-manipulated samples such as human blood. These 
properties were chosen to adhere to the guidelines of point-care-testing devices previously elucidated, 
so that the sensor can act as a POCT platform for sepsis and other possible diagnostic applications. 
This thesis discusses the steps taken to develop, demonstrate and tune the sensor properties. 
3.1 Sensor development for biomolecule detection objectives 
 Various materials were considered to achieve a colorimetric sensing platform. The ideal 
material had to demonstrate a distinct range of colours to stimuli that was easily distinguishable to the 
naked eye, and possess functional groups for conjugation to receptor components. Polydiacetylenes 
(PDAs), a class of conjugated polymers possessing unique optical properties,91 fulfilled these 
requirements and were previously demonstrated to detect biomolecule in various sensing platforms.92 
The alternating ene-yne polymer backbone structure of PDAs allows them to absorb multiple photons 
93 and express a dark blue colour when the diacetylene monomers undergo photoinduced 
topopolymerisation.94 External stimuli to the polymer backbone,95 such as the surface pressure caused 
by receptor-ligand interactions at the polymer surface, have been demonstrated to cause the polymer 
to display a colour transition progressing through a gradient of colours from blue to purple to bright 
red.96-98 The colour transition can be quickly analysed with absorbance spectrophotometry for 
quantitative evaluation.99 In addition, the diacetylene monomers are composed of a hydrocarbon chain 
with a single carboxyl group at one end, ideal for directed conjugation to other materials. For 
example, a commercially available diacetylene monomer was previously conjugated to polar 
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compounds to improve its amphiphilic properties,100 or to various ligands such as antibodies and 
enzymes for detection of target molecules.92 
 Previous PDA sensors have commonly employed solid-state approaches such as silica-
supported 101 and glass-supported 99, 102 thin films, while solution-based sensors have utilised liposome 
structures.103, 104 The problem with the existing solution-based approach is that only purified, single 
target samples can be used, and separation of liposomes from solution is not possible without 
specialised equipment. To address this, a new solution-based platform has been developed where 
amphiphilic PDA is used to coat superparamagnetic iron oxide nanoparticles (SPIONs) to form 
colorimetric, magnetically separable sensors. SPIONs were chosen as the ideal magnetic materials 
because they are easily synthesised, demonstrate magnetism only when an external magnetic field is 
applied, achieve similar activity as ferromagnetic materials, and retain negligible residual magnetism 
when the field is removed.105-107 Bovine serum albumin (BSA), a cheap, commonly available serum 
protein, is used to functionalise the sensor surface. The functionalised sensors are used to detect anti-
BSA antibodies in native antiserum solution in order to demonstrate its colorimetric and magnetic 
separation properties. This work is significant as it introduces a new sensing platform for potential 
use in POCT applications, capable of capturing and detecting biomolecules. 
Specific objectives for this work have been: 
1. Synthesis of amphiphilic diacetylene monomers. 
2. Synthesis of PDA-coated SPIONs. 
3. Visual and spectroscopic evaluation of colour responsiveness and magnetic separability. 
4. Demonstration of capture and colorimetric detection of a biomolecule from a complex 
solution. 
3.2 Sensor tuning objectives 
 Following the development and demonstration of biosensor performance, optimisation of the 
sensor was required. A proposed theory in earlier work was that colour responsiveness could be tuned 
by varying the amount of PDA, since it should be expected that higher concentrations of PDA will 
provide a larger percentage of crosslinked networks.98 Improving the lower detection limit was also 
critically important, especially for the detection of biomarkers such as C-reactive protein, where 
serum concentrations above 0.01 mg/mL are indicative of sepsis.41 This works describes the 
optimisation of coating amphiphilic PDA on SPIONs and tuning of the colorimetric and magnetic 
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separation properties, leading to an improved lower detection limit than previously reported. Tuning 
the colour response is achieved by varying the weight percent ratio of amphiphilic PDA to SPIONs 
during fabrication while keeping the amount of SPIONs constant. Optimisation is demonstrated by 
surface functionalisation with antibodies, compared to the previously demonstrated sensor utilising 
bovine serum albumin, additionally demonstrating the versatility of the biosensor for the detection of 
other biomarkers and materials.  
Specific objectives for this work have been: 
1. Tuning the colorimetric response by varying the PDA concentration used in sensor 
fabrication. 
2. Evaluation of varying PDA concentrations on magnetic separability. 
3. Determination of the optimal PDA to SPION ratio for sensor fabrication. 
4. Demonstration of sensor’s versatility for biomolecule detection by functionalisation with 
antibodies. 




4.0 Development of a Colorimetric, Superparamagnetic Biosensor 
for the Capture and Detection of Biomolecules 
4.1 Introduction 
 This section of the thesis describes the development of the surface-functionalisable core-shell 
particle biosensor composed of a superparamagnetic iron oxide nanoparticle (SPION) core and an 
amphiphilic polydiacetylene (PDA) shell, capable of measurable colorimetric sensing and simple, 
rapid magnetic separation for the capture and detection of biomarkers (Figure 2). The diacetylene 
monomer 10,12-pentacosadiynoic acid was chosen because of its chemical structure, and previous 
demonstrations of its ability to from protein sensing 108 to optical detection of foodborne pathogens.99, 
109 SPION was chosen because of their simple synthesis and superparamagnetic properties, allowing 
for simple and rapid magnetic separation of captured biomolecules. Nanoprecipitation was used to 
fabricate the sensors, which appear as macroscopic particles that are easily visualised with the naked 
eye. The sensors were functionalised with bovine serum albumin (BSA) to detect and capture anti-
BSA antibodies from a complex antiserum solution. This sensor is significant because it is the first to 
combine PDA and SPIONs to form a colorimetric, magnetically separable biosensor, and is 





Figure 2. Schematic representation of colorimetric, magnetically separable functionalised Lys-
PCDA/SPION particles, describing the capturing and sensing of a target biomolecule from a 
complex solution. On the left are photographs of actual magnetically separated Lys-PCDA/SPIONs 
before and after the detection of ethanol. 
 
4.2 Experimental Methods 
4.2.1 Synthesis of hydrophobic superparamagnetic iron oxide nanoparticles 
 Oleic acid-coated SPIONs (OA-SPIONs) were synthesised according to a previously 
described coprecipitation method, with minor modifications.110 Briefly, excess oleic acid was used to 
promote a uniform coating on the SPIONs, while undecylenic acid was not used. The OA-SPIONs 
were characterised using a Philips CM10 transmission electron microscope. The hydrophobic coating 
was verified by dispersing the OA-SPIONs in a chloroform/water mixture (see Appendix A). 
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4.2.2 Amphiphilic modification of diacetylene monomer 
 The diacetylene monomer 10,12-pentacosadiynoic acid (PCDA) (Alfa Aesar) was modified 
with a hydrophilic lysine derivative, Nα,Nα-bis(carboxymethyl)-L-lysine hydrate (BCML) (Sigma 
Aldrich) via two-step coupling chemistry using 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide 
(EDC) and N-hydroxysuccinimide (NHS) (see Appendix A). The NHS-activated PCDA was reacted 
with a 1.2 molar excess of BCML, precipitated and washed with 1 M hydrochloric acid, extracted 
with chloroform/ethanol (1:1), then filtered and dried to obtain a purplish white paste. To confirm the 
synthesis of the lysine-modified PCDA (Lys-PCDA), the product was characterised using ¹H nuclear 
magnetic resonance spectroscopy (Bruker Avance 300MHz). 
4.2.3 Fabrication of Lys-PCDA/SPION core-shell particle 
 To prepare the Lys-PCDA/SPION particles, the OA-SPIONs and Lys-PCDA were mixed 
together in tetrahydrofuran. Self-assembly of Lys-PCDA onto OA-SPIONs was achieved through 
dropwise addition of the mixture into Milli-Q water under constant stirring. The particles were 
washed several times with water, then irradiated at 254 nm with a UV crosslinker (UVP CL-1000), 
causing polymerisation of the Lys-PCDA surface coating. This was marked by a visible colour 
change of the particles from brown to a black to dark blue colour, depending on the percent 
concentration of Lys-PCDA added. 
4.2.4 Detection of anti-bovine serum albumin antibodies 
 Particles used for the detection of anti-BSA antibodies were synthesised as before, excluding 
UV irradiation. To functionalise the particle surface with BSA, they were activated with EDC and N-
hydroxysulfosuccinimide (sulfo-NHS) in a 0.1 M MES buffer, pH 4.7, and washed, repeated twice, 
then mixed end-over-end with 20 mg/mL BSA in sterile 0.1 M PBS buffer, pH 7.2, overnight at 4C. 
The particles were washed to remove unconjugated BSA and mixed with 40 mM ethanolamine in 
water, pH 8.3, to block unreacted sulfo-NHS sites. The particles were washed several times again, 
then the Lys-PCDA coating was crosslinked at 254 nm in 10 bursts of 1 mJ/cm². All washes were 
performed with PBS buffer, using a magnet to separate the particles from the decanted solution.  
 The assay was performed by incubating approximately 1.25 mg/mL of BSA/Lys-
PCDA/SPION particles in 1 mL aliquots of various concentrations of rabbit anti-BSA antiserum, of 
which anti-BSA polyclonal antibodies formed a ~10% fraction of the antiserum proteins according to 
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manufacturer’s specifications (Rockland Immunochemicals Inc.). The particles were continuously 
mixed with a low speed vortex mixer overnight, then washed several times with PBS buffer using 
magnetic separation. The particle color transition was measured with a BioTek Epoch UV-visible 
spectrophotometer in the visible absorbance spectrum. 
The colour transition was quantified as a colorimetric response (CR %), using the following:111 
	% 100% 
where PB = Ablue/(Ablue + Ared), A was the UV-visible absorbance value of the particle’s “blue” state at 
650 nm or the “red” state at 550 nm, and PB0 and PB1 were the respective colorimetric ratios of the 
particles before and after the assay. 
4.3 Results and Discussion 
4.3.1 Characterisation of Lys-PCDA/SPION-based biosensors  
 The objective in this study was to develop a magnetically separable sensor capable of 
displaying a distinct colorimetric response to receptor-ligand interactions, and thus suitable for POCT 
sensing applications. By incorporating a hydrophilic lysine derivative, the Lys-PCDA/SPIONs 
display sustained suspension in aqueous solutions compared to particles formed with unmodified 
PCDA (Figure 3(A-B)), essential for maximising particle interaction with aqueous soluble analytes 
such as serum proteins. To confirm the colour functionality of the sensor, the particles were added to 
ethanol, resulting in a sharp colour transition from a blue to a red state, similar to previously 
described PCDA vesicles.99, 108, 112 This also resulted in an absorbance peak shift from 650 nm to 550 
nm (Figure 1(C-E)). Ethanol has been previously reported to cause PDA vesicles to change from blue 
to red, due to swelling of the PDA layers as ethanol interacts with the PDA carboxyl group through 
hydrogen bonding.112 Applying a magnetic field to the particles in solution resulted in quick particle 
separation without causing changes in colour. In addition, the particles remained magnetically 
separable after undergoing the colour transition. This was marked by the solution becoming clear and 
colourless and was easily observed with the naked eye due to the particle size (Figure 3(D)), 
illustrating the successful capture of particles after a sensing event. In rapid diagnostic applications 
involving complex or non-manipulated fluids, the ability to quickly and easily separate analytes for 
analysis without adversely affecting the sensor is a necessary functionality, which the sensor particles 
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gradients. In this study, one objective was to demonstrate the suitability of the Lys-PCDA/SPIONs 
for POCT applications by demonstrating the detection of receptor-ligand interactions, using BSA-
functionalised sensors to detect anti-BSA antibodies. The functionalised particles exhibit a visible, 
increasing colorimetric response as the concentration of anti-BSA are increased, ranging from a 
blackish blue colour to a gradient of increasingly lighter purples (Figure 4(A)). 
 The use of anti-BSA in antiserum format highlights the importance of magnetic separability 
for analyte capture and detection, especially for POCT applications. As shown in Figure 4(A-II), the 
purified antiserum appears as a clear reddish yellow solution, which hinders accurate judgment the 
degree of colour response with the naked eye at the end of the assay. Based on current results and 
previous studies of PDA-based sensors,109 PDAs are known to exhibit a colour response ranging from 
dark purple to bright red in response to stimuli. It can be safely inferred that PDA-based sensors used 
with non-manipulated blood or other dark coloured samples would mask any colour transitions and 
make accurate interpretations of the results with the naked eye very difficult. As a result of the 
SPION cores, the particles demonstrated quick separation from solution with a common magnet, 
avoiding the need for specialised equipment to wash and observe the particles, and allowing accurate 
observation of the increased expression of purple among the different samples (Figure 4(A-III)). 
Based on the visual observations alone, Lys-PCDA/SPION particles can serve as a platform for the 

































 sensors, the 









f the visual o
visible absor







ed at the “red










” state peak 
ion of the 96
 of the color
and illustrate





































reported, including in the detection of S. typhimurium cultures 99 and amino acids.108 Quantitative 
analysis, expressed as CR %, described an increasing colorimetric response of 0.163, 0.434, 0.584, 
0.684, and 0.841% for samples with 0.5, 1, 2, 4, and 8 mg/mL anti-BSA, respectively, compared to 
particles from the 0 mg/mL anti-BSA sample (Figure 4(C)). In comparison, when the particles were 
added to ethanol, a maximum CR % of only 1.796% was achieved, indicating that approximately half 
of the possible colour response range was achieved. For diagnostic applications interested in 0-10 
mg/mL of analyte, it is expected the sensor particles could express the entire colour response range by 
optimising the ratio of Lys-PCDA to SPIONs and achieve greater colour distinctions between 
differing amounts of analyte. The colorimetric response values showed a hyperbolic regression with a 
coefficient of determination of 0.9806 (see Appendix A), indicating that if larger amounts of anti-
BSA had been tested with the Lys-PCDA/SPIONs, the full colour response range would have likely 
been realised. The results also demonstrate that the Lys-PCDA/SPIONs can be used as analytical 
biosensors in addition to semi-quantitative POCT applications. 
4.4 Conclusions 
 The simple synthesis and application of novel Lys-PCDA/SPION particles as a platform for 
the capture and detection of serum proteins was demonstrated in this study. Although only a proof-of-
concept investigation was performed, the biosensor showed a colorimetric response that corresponded 
to an increasing concentration of anti-BSA antibodies, with a lower detection limit of 0.5 mg/mL. 
Thus, in its current form, the biosensor would be useful for diagnostic applications where high 
biomarker concentrations are indicative of disease, as well as non-clinical applications where analyte 
detection is needed in the mg/mL range. Additionally, the colorimetric response was both easily 
visualised with the naked eye and could be measured with a basic UV-Vis spectrophotometer. The 
response could be accurately measured because the particles could be quickly separated from a mixed 
solution with a common magnet, eliminating the need for advanced equipment such as high-speed 
centrifuges or laborious wash techniques. Future studies are needed to improve the sensing 
performance of the particles and achieve a greater range of colorimetric response, including 
increasing the Lys-PCDA to SPION ratio. This work has demonstrated that Lys-PCDA/SPION 
particles can be quickly developed for clinical applications and address a pressing need for POCT 
platforms.   
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5.0 Optimisation of polydiacetylene-coated superparamagnetic iron 
oxide for colorimetric detection and capture of biomarkers 
5.1 Introduction 
 This section of the thesis describes the optimisation of the polydiacetylene-coated SPION 
biosensor for capturing and detection biomarkers, previously described in section 4.0. To tune the 
colorimetric response of the biosensors, various ratios of Lys-PCDA to SPION were tested during 
biosensor fabrication while keeping the SPION content constant in all compositions. Varying the 
maximum colour response of each composition was achieved by exposing the sensors to ethanol. 
Colorimetric detection was achieved by functionalising the sensors with anti-horse IgG antibody and 
incubating the sensors against purified horse IgG solution. Similar to previous studies of PDA-based 
sensors, characterisation of each sensor composition was performed with UV-visible absorption 
spectrophotometry. The work is significant because it resulted in determining the optimal ratio of 
Lys-PCDA to SPION to achieve the maximum sensor performance, including colorimetric response 
and magnetic separability. The lower detection limit was also improved to a significant biomarker 
concentration, equal to C-reactive protein levels used for diagnosing sepsis. It also demonstrates the 
versatility of the biosensor as a different receptor-ligand system is used in this work to express the 
colorimetric response. 
5.2 Experimental Methods 
5.2.1 Materials 
 10,12-Pentacosadiynoic acid (PCDA) was purchased from Alfa Aesar and purified with 0.45 
µm polytetrafluoroethylene membrane filter before use. (S)-N-(5-Amino-1-
carboxypentyl)iminodiacetic acid, cis-9-octadecenoic acid, 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide (EDC), 1-hydroxy-2,5-pyrrolidinedione, hydroxy-2,5-dioxopyrrolidine-3-sulfonicacid 
sodium salt (sulfo-NHS), and 2-aminoethanol purchased from Sigma Aldrich (Canada), NaCl, FeCl2, 
and Fe2(SO4)3 purchased from Fisher Scientific (Canada), and N,N-diethylethanamine, NH4OH, HCl, 
CHCl3, tetrahydrofuran (THF), and ethanol purchased from EMD Millipore were used as received. 
All solvents used were HPLC grade. Horse IgG and rabbit anti-horse IgG antibodies were purchased 
from Rockland Immunochemicals Inc. and washed with sterile PBS buffer (0.1M sodium phosphate, 
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0.15M NaCl, pH 7.2) using Amicon Ultra-15 10K centrifugal filter units from EMD Millipore before 
use. 
5.2.2 Synthesis 
 Oleic acid-coated SPIONs (OA-SPIONs) and amphiphilic PDA (Lys-PCDA) were 
synthesised using procedures as previously described in section 4.2. 
5.2.3 Biosensor fabrication 
 Functionalised amphiphilic PDA-coated SPION sensors (Lys-PCDA/SPIONs) were 
fabricated at various weight percentages (wt%) of Lys-PCDA ranging from 60-95 wt% while keeping 
constant the amount of OA-SPIONs, similar to the previously described procedure in section 4.2. 
Briefly, Lys-PCDA and OA-SPIONs were mixed in THF and added dropwise to Milli-Q water at 12 
mL/h under mechanical stirring at 820 rpm, stirred for 20 minutes, then washed using magnetic 
separation. Sensors were functionalised with equal amounts of anti-horse IgG antibody according to 
the molar fraction of Lys-PCDA in each wt% sample, via two-step EDC/sulfo-NHS conjugation in 
PBS buffer. Unreacted sulfo-NHS was blocked with 2-aminoethanol. Fabrication was completed with 
irradiation at 254 nm in 3 bursts of 1 mJ/cm2.  
5.2.4 Antibody assay 
 Equal aliquots of each wt% sample of Lys-PCDA/SPIONs were incubated with 4 mL of 0, 
0.01, 0.1, 0.5, and 1 mg/mL horse IgG in PBS buffer and mixed at room temperature with gentle 
orbital shaking until marked colour changes were observed (6 hours). 
5.2.5 Characterisation 
 The antibody assay was monitored at set time intervals for the appearance of colour change 
and photographed at each interval in a controlled white-surfaced digital photo box with identical 
lighting and camera settings. UV-visible absorption measurements were recorded at the end of the 
antibody incubation with a Biotek Epoch spectrophotometer using Greiner Bio-One UV-Star 96-well 
microplates. Lys-PCDA/SPIONs were washed 3 times with PBS buffer before spectroscopic analysis 
to remove any interference effects from the horse IgG solution. Spectra with a wavelength range of 
400 to 700 nm, in 10 nm increments, were recorded. The color transition was quantified as a 




where PB = Ablue/(Ablue + Ared), A was the UV-visible absorbance value of the particle’s “blue” state at 
650 nm or the “red” state at 540 nm, and PB0 and PB1 were the respective colorimetric ratios of the 
particles before and after the assay. 
5.3 Results and discussion 
5.3.1 Optimisation of polydiacetylene amount used in sensor fabrication 
 The objective of this work was to optimise and tune the colorimetric performance of 
previously described Lys-PCDA/SPION sensors by varying the ratio of amphiphilic PDA to 
hydrophobic SPIONs during sensor fabrication. Normalised absorption spectra and visual 
comparisons of the sensors not used in the assay are shown in Figure 5 and clearly demonstrate the 
effects of increasing the amount of PDA, which are three-fold. First, increasing the amount of PDA 
results in distinct increases in the initial blue colour, as well as a greater colour response when 
perturbed with ethanol (Figure 5(A-C)), which has been previously reported to swell PDA surfaces 
and affect a transition to the “red” state.112 For example, sensors composed of 95 wt% PDA 
demonstrated a 23.054% colorimetric response compared to a 0.678% response from 60 wt% PDA 
sensors (Figure 5(D)). 
 Second, increasing the amount of PDA assists in shielding the UV-visible absorption 
interference caused by the black SPION cores, up to 90 wt% PDA, indicated by the absorbance 
values between 400-600 nm. Previous free-floating PDA vesicles have demonstrated decreasing 
absorption values from ~590 nm to 400 nm.98 In comparison, the Lys-PCDA/SPIONs do not display 
this trend. At lower PDA wt%, markedly noticeable among 60-75 wt%, the PDA surface coating is 
not thick enough to reduce absorption by the SPION core. However, it is important to note that this 
interference does not affect the “red” state reading at 540 nm if enough PDA is used during 
fabrication, indicated by the marked peaks at 540 nm among the 75-95 wt% PDA sensors (Figure 
5(C)). 
 Third, increasing the amount of PDA greatly improves the aqueous dispersion of the Lys-
PCDA/SPION sensors. This is visually demonstrated by the denser solutions at higher PDA wt%, in 
comparison to the increasingly clear solutions at 70-60 wt% PDA (Figure 5(A)). During wash steps of 
biosensor fabrication, the lower wt% sensor particles were observed to preferentially float at the 
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surface of the aqueous solutions. This prevented efficient magnetic separation and retention of the 
Lys-PCDA/SPIONs, resulting in the loss of sensor particles. However, high wt% was also observed 
to be undesirable, specifically at 95 and 90 wt% PDA. During wash steps, these sensors required 
longer separation times, and a small fraction of these sensor particles were observed in wash run-off, 
particularly the 95 wt% Lys-PCDA/SPIONs. In addition to reducing the absorption interference 
caused by the SPION cores, it is highly suspected the thicker PDA coatings also reduced the net 
saturation magnetisation of the SPION cores, and thus lowering their magnetic separability. It has 
been previously shown that magnetic separation of SPIONs is dependent upon the concentration and 
aggregation of the magnetic material in the net system.113, 114 Thus, increasing the amount of non-
magnetic material between SPIONs, such as found in the high wt% PDA sensors, would be expected 
to interfere with the transient aggregation of neighbouring SPIONs that allows their separation to 
occur. This observation coincides with a previous study which found that increasing the amount of 
non-magnetic material in relation to the amount of hydrophobic SPIONs present in the system 





Figure 5. Characterisation of Lys-PCDA/SPION sensors. (A) Photographs of varying PDA wt% 
sensors. (B) Absorption spectra in PBS. (C) Absorption spectra post-ethanol. (D) Colorimetric 
response of sensors to ethanol. 
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5.3.2 Optimisation of colorimetric biomolecule detection 
 To optimise the colorimetric detection, each sensor composition was exposed to varying 
concentrations of horse IgG solution. As shown in Figure 6, the sensors composed of 85-95 wt% 
PDA demonstrated the most noticeable colour transitions in all four concentrations tested (0.01, 0.1, 
0.5, and 1 mg/mL), making a visible transition towards the red state and appearing as the purple 
colour phase after 6 hours. Similar to previous visual observations when tested against ethanol, 
increasing the wt% of PDA in the sensor resulted in a greater colour response to biomolecule 
detection. However, after washing the sensors for spectrophotometry analysis, 90 and 95 wt% sensors 
showed marked reductions in sensor particle retention, with 95 wt% sensors exhibiting less retention 
than 90 wt%. This is consistent with earlier observations noted above and indicates that utilising too 
much PDA can result in suboptimal magnetic separability.  
 
Figure 6. Photographs of Lys-PCDA/SPION sensors of varying PDA wt%. (A) 1 mg/mL horse 




Figure 7. Absorption spectra of Lys-PCDA/SPION sensors of varying PDA wt%, normalised to 
650 nm. (A) 1 mg/mL horse IgG. (B) 0.5 mg/mL horse IgG. (C) 0.1 mg/mL horse IgG. (D) 0.01 
mg/mL horse IgG. 
 The absorption spectra are shown in Figure 7 and highlight the significance of PDA 
concentrations used in the sensor fabrication to achieving optimal performance. Spectra for 60-65 
wt% appeared very similar to the controls in PBS (Figure 5(B)), indicating that not enough PDA was 
present to produce a colour response. At the lower PDA concentrations of 70-80 wt%, little colour 
change was visually observed and appearance of a peak at 540 nm, indicative of the red state, was not 
detected, signifying no sensing had likely occurred. This was expected after sensor fabrication, as the 
60-80 wt% sensors did not appear as blue as previously described PDA-based sensors. In comparison, 
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based diagnosis of critical illnesses such as sepsis. Serum concentrations greater than 0.01 mg/mL of 
C-reactive protein (CRP), a commonly used biomarker for diagnosing sepsis 37 and several other 
illnesses,38 are indicative of sepsis.41 The 85-95 wt% sensors all demonstrated different colorimetric 
responses when incubated with 0.01 mg/mL, compared to the higher concentrations of target analyte. 
Quantitatively, the 85 wt% PDA sensor demonstrated a 2.01% and 1.70% colorimetric response at 0.5 
and 0.1 mg/mL when normalised against the colorimetric response at 0.01 mg/mL, while the 90 and 
95 wt% sensors showed respective colorimetric responses of 1.48% and 1.42%, and 1.37% and 1.27% 
(Figure 10). 
 
Figure 10. Colorimetric response of 85, 90 and 95 wt% PDA compositions of Lys-PCDA/SPION 
sensors, normalised against the colorimetric response at 0.01 mg/mL horse IgG. 
 
 Based on the results, the optimal ratio of Lys-PCDA to hydrophobic SPIONs to use during 
sensor fabrication is 85 wt% to achieve optimal sensor performance. At PDA ratios below 80 wt%, 
the sensors demonstrate weak colorimetric sensing properties, likely a result of insufficient amounts 
of PDA in the system. At lower ratios below 65 wt%, the insufficient amount of Lys-PCDA hinders 
both the colorimetric sensing and magnetic separability properties. While high ratios of 90-95 wt% 
 
 37 
PDA demonstrate greater visual colour responsiveness, complete magnetic retention was not 
observed and the reduction in sensor particles resulted in lower than expected measurable 
colorimetric responses, especially when compared against the CR% values at 0.01 mg/mL. 
5.4 Conclusions 
 In summary, previously described Lys-PCDA/SPION biosensors for point-of-care testing 
applications was optimised, with the 85 wt% PDA composition showing the best performance. 
Additionally, the sensors successfully demonstrated a lower detection limit of 0.01 mg/mL, 
significantly better than the previously reported 0.5 mg/mL. Horse IgG/anti-horse IgG binding was 
used in this work as a cost-effective optimisation of the biosensor and to demonstrate the versatility of 
the biosensor for detecting different target analytes. The optimisation of the biosensor presented in 
this work highlights the sensor as a potential diagnostic platform to meet the urgent need of point-of-




6.0 Conclusions and Recommendations 
6.1 Concluding Summary 
 This thesis began with an overview of the requirements and benefits of point-of-care testing 
(POCT) systems for diagnosing critical illnesses, with a specific focus on sepsis. A comprehensive 
literature review followed on the most commonly studied biomarkers of sepsis, with a focus on their 
diagnostic relevancy and applicability to POCT systems, to establish the serum protein levels that 
require detection. Available systems were also identified to determine the diagnostic issues not 
addressed by current biomarker-based sensors. From this research, the following research objectives 
were established: 1) to develop a biosensor capable of colorimetric detection of small concentrations 
of biomolecules and capture of target analytes from complex solutions through simple magnetic 
separation, and 2) to demonstrate tuning of the colorimetric response and versatility of the sensor for 
detecting different analytes. From these objectives, polydiacetylenes, a class of conjugated polymers, 
were chosen for colorimetric sensing because of their unique optical property of transitioning from 
blue to red in response to receptor-ligand interactions. Superparamagnetic iron oxide was chosen to 
form the magnetically separable core of the sensor because of their simple synthesis and 
demonstrated superparamagnetism. 
 Using the concept of nanoprecipitation, polydiacetylene-coated SPION sensor particles were 
successfully developed and functionalised for biomolecule detection and capture from a complex 
antiserum solution. The benefits of magnetic separation in the sensor design were also demonstrated. 
A lower detection limit of 0.5 mg/mL was achieved, applicable to many sensing application, but 
required a more sensitive lower detection limit for sepsis biomarker detection. 
 Tuning of the biosensor’s colorimetric response was achieved by varying the ratio of PDA to 
SPION during sensor fabrication, showing improved colour responsiveness with increasing PDA 
concentrations. Low PDA concentrations resulted in poor magnetic separability and colorimetric 
performance, while using very high PDA concentrations resulted in some loss of sensor retention 
during magnetic separation, resulting in an optimal ratio of 85 wt% amphiphilic PDA/15 wt% 
hydrophobic SPIONs being determined. In addition, the versatility of the biosensor was demonstrated 
by utilising a different receptor-ligand system, and the lower detection limit was improved to 0.01 
mg/mL, a diagnostically relevant concentration when using C-reactive protein to diagnose sepsis. 
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 This work has been significant because it establishes a new sensing platform with the 
capacity to serve in a wide range of POCT applications, demonstrating simple operation and 
fabrication and visually observable colorimetric detection. The demonstrated target versatility of the 
biosensor is indicative of its potential adaption to other sensing applications beyond disease 
diagnosis, ranging from personal care to food safety. 
6.2 Recommendations for Future Work 
 With the demonstration of Lys-PCDA/SPION sensor particles as a viable platform for point-
of-care testing, further experimentation could be pursued to achieve specific colour responses to 
specific biomarker concentration ranges. Additionally, achieving even lower detection limits to allow 
the sensing of biomarkers in ng/mL concentrations would be a major milestone in the development of 
POCT systems for sepsis, given the large demand for diagnostic systems with increasing sensitivity. 
This could be achieved by determining the optimal amount of receptors to functional a given sensor 
surface area. Exploring the effects of incorporating different materials into the amphiphilic PDA 
surface, as well as using other polar molecules to modify the native polydiacetylene, may lead to 
enhanced colorimetric properties. For example, previous studies on PDA-based sensors have included 
phospholipids into PDA structures to adjust the amount of crosslinking between diacetylene 
monomers, while other studies have modified native PDA with glycolipids for detection of certain 
bacteria. The work in this thesis utilised readily available receptor and ligand materials to achieve 
cost-effective demonstrations of the biosensor’s properties. The successful research presented here 
warrants that future experimentations should use receptors against specific biomarkers of sepsis, as 
well as receptors for biomarkers of other diseases and toxic environmental materials. 
In summary, the significant works discussed in this thesis can be further developed by: 
1. Exploring the inclusion of different materials within the PDA surface of Lys-PCDA/SPION 
sensors. 
2. Investigating the effects of modifying native PDA with different polar molecules other than 
the lysine derivative currently used. 
3. Establishing the optimal ratio of receptor molecules for a defined surface area of the 
biosensor. 
4. Discovering new analytes that can be colorimetrically detected with the biosensor by 
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Synthesis of Lys-PCDA 
 The diacetylene monomer 10,12-pentacosadiynoic acid (PCDA) (Alfa Aesar) was modified 
with a hydrophilic lysine derivative, Nα,Nα-bis(carboxymethyl)-L-lysine hydrate (BCML) (Sigma 
Aldrich) via a two-step coupling chemistry with 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide 
(EDC) and N-hydroxysuccinimide (NHS) (Figure A2(A)). PCDA was dissolved in a 1:1 mixture of 
chloroform (HPLC-grade) and ethanol with at least 1.25 molar excess of NHS and 1.5 molar excess 
of EDC and stirred overnight to form an amine-reactive PCDA intermediate. The intermediate was 
washed with 20% w/v brine and extracted with chloroform, dried over anhydrous sodium sulfate to 
form a white powder, then dissolved in tetrahydrofuran (THF) to form a 20 mM solution. A 1.2 molar 
excess of BCML was added to Milli-Q water to 20 mg/mL and dissolved under stirring via dropwise 
addition of triethylamine (TEA). The entire BCML solution was added dropwise to the NHS-
activated PCDA in THF under stirring over a duration of 30 minutes with a syringe pump, then stirred 
sealed overnight. 1 M hydrochloric acid (HCl) was added dropwise to the solution until a white 
emulsion formed (~pH 1), concentrated with a rotary evaporator, washed with 1 M HCl several times, 
and dried. Finally, the recovered precipitate was dissolved in a 1:1 mixture of chloroform and 
methanol, filtered with 0.45 µm PTFE membrane, and dried to produce a purplish white powder. 
Appearance of peaks at 1.98, 2.67, 2.77, 3.36, and 7.68 ppm and the increased intensity at 2.50 ppm 
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Assay of rabbit anti-BSA antiserum 
 Rabbit anti-BSA antiserum (Rockland Immunochemicals Inc.) was reconstituted according to 
manufacturer’s instructions, then washed twice with 0.1M PBS buffer, pH 7.2 (Thermo Scientific) 
using Amicon Ultra-15 10 kDA MWCO tubes (EMD Millipore), centrifuged at 4000 xg for 20 
minutes, to remove sodium azide. The antiserum solution was diluted with PBS buffer to the 
concentrations of 80, 40, 20, 10, 5, 2, and 1 mg/mL total antiserum protein. Manufacturer 
specifications indicated ~10% of the total antiserum protein was anti-BSA antibodies. 
 The BSA-functionalised Lys-PCDA/SPION particles were mixed with 1 mL aliquots of each 
anti-BSA antiserum concentration, as well as negative controls of PBS buffer and of 20 mg/mL 
purified lysozyme from chicken egg white (Sigma Aldrich) in PBS, in 7 mL scintillation vials. 
Mixing was monitored for the first hour, then left to run overnight. Total mixing time was 18.5 hours. 
The positive control showed no visible change. Each anti-BSA sample of particles was washed with 
PBS buffer 4 times, until the presence of foaming was no longer observed, then dispersed in 0.9 mL 
PBS buffer. 3 0.3 mL aliquots were taken from each sample and added to a sterile 96-well 
polypropylene microwell plate (Grenier Bio-One). Visible absorbance spectra were recorded (400-
700 nm) in 10 nm increments with a Biotek Epoch UV-visible spectrophotometer. Absorbance 
readings were performed 3 times, for a total of 3 triplicates per sample. 
 To calculate the colorimetric response (CR%), the absorbance values at 550 and 650 nm were 
used in the following equations: 
	% 100% 
where PB = Ablue/(Ablue + Ared), A was the UV-visible absorbance value of the particle’s “blue” state at 
650 nm or the “red” state at 550 nm, and PB0 and PB1 were the respective colorimetric ratios of the 




Table A1. Calculation of colormetric values (CR %). 
Anti-BSA 
(mg/mL) 
8 4 2 1 0.5 0 
A550 0.544556 0.629222 0.458778 0.560778 0.549778 0.593667 
A650 0.540444 0.626444 0.457667 0.561111 0.553111 0.599222 
PB1 0.498105 0.498894 0.499394 0.500149 0.501511 0.502329 
PB0 0.502329 0.502329 0.502329 0.502329 0.502329 0.502329 
CR % 0.840712 0.683758 0.584243 0.43399 0.162728 0 
 
OriginPro 8.5 was used to perform regression analysis, using the non-linear curve fit tool. A 
hyperbolic curve achieved the best fit of the data (Figure A3). 
 
 
Figure A3. Regression analysis of colorimetric response values. 
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